Solomon Jacqueline M, Paul Friedemann, Chien Claudia, Oh Jiwon, Rotstein Dalia L
University of Toronto, Department of Medicine, Toronto, ON, Canada.
Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité Universitaetsmedizin Berlin, Berlin, Germany.
Ther Adv Neurol Disord. 2021 May 9;14:17562864211014389. doi: 10.1177/17562864211014389. eCollection 2021.
Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing, inflammatory disease of the central nervous system marked by relapses often associated with poor recovery and long-term disability. Magnetic resonance imaging (MRI) is recognized as an important tool for timely diagnosis of NMOSD as, in combination with serologic testing, it aids in distinguishing NMOSD from possible mimics. Although the role of MRI for disease monitoring after diagnosis is not as well established, MRI may provide important prognostic information and help differentiate between relapses and pseudorelapses. Increasing evidence of subclinical disease activity and the emergence of newly approved, highly effective immunotherapies for NMOSD adjure us to re-evaluate MRI as a tool to guide optimal treatment selection and escalation throughout the disease course. In this article we review the role of MRI in NMOSD diagnosis, prognostication, disease monitoring, and treatment selection.
视神经脊髓炎谱系障碍(NMOSD)是一种中枢神经系统复发性炎性疾病,其特征为复发频繁,常伴有恢复不佳和长期残疾。磁共振成像(MRI)被认为是及时诊断NMOSD的重要工具,因为它与血清学检测相结合,有助于将NMOSD与可能的模仿疾病区分开来。虽然MRI在诊断后疾病监测中的作用尚未完全确立,但MRI可能提供重要的预后信息,并有助于区分复发和假性复发。越来越多的亚临床疾病活动证据以及新批准的、高效的NMOSD免疫疗法的出现,促使我们重新评估MRI作为一种在整个疾病过程中指导最佳治疗选择和升级的工具。在本文中,我们回顾了MRI在NMOSD诊断、预后评估、疾病监测和治疗选择中的作用。